Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343933 | 0.91 | EPAS1 (0.38) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1342509 | 0.91 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1344436 | 0.90 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1341700 | 0.90 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1344277 | 0.89 | EPAS1 (0.36) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1344905 | 0.88 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL12130348 | 0.88 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL13983342 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL13492117 | 0.87 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1344183 | 0.87 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19RORCEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-8293778-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293778-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-10-23 | — | — | US | disclosed |
| EP-1773790-B1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-8063028-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063028-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063064-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063064-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-20060025462-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2006010545-A1 | BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| EP-1608629-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050234236-A1 | Process for preparing pyridazinone compounds | ROCHE PALO ALTO LLC | 2005-10-20 | — | — | US | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
| WO-2004085406-A1 | BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | CYP3A4 2749/4885CYP2C9 3253/4885CYP2C19 2274/4885 |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | CYP3A4 264/4885CYP2C9 808/4885CYP2C19 430/4885 |
| US-20050234236-A1 | Process for preparing pyridazinone compounds | CYP2A6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP3A4 73/4885CYP2C9 226/4885CYP2C19 105/4885 |
| US-20060025462-A1 | Heterocyclic antiviral compounds | MAVS, IRF3, ZC3HAV1 | CYP3A4 893/4885CYP2C9 1216/4885CYP2C19 750/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | CYP3A4 2342/4885CYP2C9 3005/4885CYP2C19 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.